GYRE (Gyre Therapeutics Inc.) stock: $7.55, $841.9M market cap, $57.3M cash, $784.6M EV, $983.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
F351
Phase 3 · Active Modality: small molecule (structurally modified pirfenidone derivative)
Aliases hydronidone
Target TGF-beta1 signaling pathway
Partnerships GNI Japan / GNI Group: Hydronidone IP rights for mainland China (right of first offer for global); RMB 8.3M on NDA inspection pass + RMB 49.6M on NMPA approval; 12 annual royalties (8-16% of sales)
Indications- Chronic hepatitis B (CHB)-associated liver fibrosis (PRC) (Phase 3)
- MASH-associated liver fibrosis (U.S.) (Phase 1)
Status note Lead candidate. Pivotal Phase 3 in CHB liver fibrosis met primary and key secondary endpoints (May 2025); NMPA granted priority review (Mar 2026), NDA submitted Mar 22, 2026 and accepted May 12, 2026 (conditional approval sought); Phase 3C confirmatory trial underway. U.S. MASH program: Phase 1 in healthy volunteers completed, IND discussions with FDA ongoing for Phase 2.
ETUARY
Approved · Active Modality: small molecule
Aliases pirfenidone
Target TGF-β1; TNF-α
Indications- Idiopathic pulmonary fibrosis (IPF) (Approved)
- Pneumoconiosis (PRC) (Phase 3)
- Radiation-induced lung injury (RILI) (Phase 2/3)
Status note First-in-class PRC approval 2011; National Reimbursement Drug List 2017; leading PRC market position. Pneumoconiosis 52-week Phase 3 enrolled 272 patients (2025). RILI adaptive Phase 2/3 initiated April 2026.
Etorel
Approved · Active Modality: small molecule
Aliases nintedanib ethanesulfonate soft capsules
Partnerships Jiangsu Wangao Pharmaceuticals: drug registration certificate and marketing authorization holder transfer (May 2024)
Indications- IPF / SSc-ILD / progressive pulmonary fibrosis (PPF) (Approved)
Status note Commercial sales in the PRC commenced June 2025.
Contiva
Approved · Active
Aliases avatrombopag maleate
Target thrombopoietin receptor
Indications- Thrombocytopenia in chronic liver disease (adults undergoing elective procedures) (Approved)
- Chronic immune thrombocytopenia (ITP) (Approved)
Status note Commercial product; no pipeline disclosure in excerpts.
CG001419
Phase 1 · Active Modality: targeted protein degrader (oral)
Target TRKA (tropomyosin receptor kinase A)
Indications- Pain (non-opioid) (Phase 1)
- Solid tumors (TRK gene abnormalities) (Phase 1)
Status note Acquired via Cullgen. Phase 1 in 78 healthy volunteers completed Dec 2025 (Australia); Phase 1 in solid tumors ongoing in China.
CG009301
Phase 1 · Active Modality: targeted protein degrader
Target GSPT1
Indications- High-risk hematologic malignancies (including AML) (Phase 1)
Status note Acquired via Cullgen. Phase 1 dose-escalation in China initiated April 2025.
F573
Phase 2 · Active
Target caspases
Indications- Acute / acute-on-chronic liver failure (ALF/ACLF) (Phase 2)
Status note Phase 1 in healthy volunteers (PRC) completed; multi-stage Phase 2 initiated March 2023.
F230
Phase 1 · Active Modality: small molecule
Target Endothelin receptor A
Indications- Pulmonary arterial hypertension (PAH) (Phase 1)
Status note Selective endothelin receptor A antagonist. IND approved by NMPA May 2024; first subject enrolled in Phase 1 June 2025.
F528
Preclinical · Active Modality: anti-inflammatory small molecule
Target multiple inflammatory cytokines
Indications- Chronic obstructive pulmonary disease (COPD) (Preclinical)
Status note Designed to inhibit multiple inflammatory cytokines; IND to NMPA anticipated in 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.